Bone Abstracts

Ibandronate (IBN), a nitrogen-containing bisphosphonate, and eldecalcitol (ELD), an active vitamin D3 derivative, are used for osteoporosis treatment. Vitamin D3 often used in combination therapies, however, there are no reports on the effects of combined IBN and ELD treatment for osteoporosis.In this study, we examined the effects of combination treatment with IBN and ELD in aged ovariectomized rats. Eight-month-old Wistar-Imamichi...

Eldecalcitol (ED-71; ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, was approved to treat osteoporosis in Japan in 2011. The endothelial protective effect of vitamin D3 in osteoporosis is not clear. This study evaluated the endothelial protective effect of ELD in ovariectomized (OVX) rats.ELD (20 ng/kg) was orally administered five times a week for 4 weeks from 1 day after OVX surgery. Four weeks after surgery, flow-mediated dilation (...

Eldecalcitol (ED-71; ELD), a 2β-hydroxypropyloxy derivative of 1α,25(OH)2D3, was approved to treat osteoporosis in Japan in 2011. Raloxifene (RAL), a selective estrogen receptor modulator, is available to treat or prevent postmenopausal osteoporosis. In this study, we compared the effects of combining ELD and RAL against each monotherapy in osteoporotic rats.Eight-month-old female Wistar–Imamichi rats were ovariectomi...